David Borquez, MD

Articles

Paclitaxel and UFT Plus Oral Calcium Folinate in Pretreated Metastatic Breast Cancer

Ute Klaassen, MD;David Borquez, MD;Stephanie Lang, MD;Carsten Oberhoff, MD;Andreas Harstrick, MD;Siegfried Seeber, MD, PhD;Steven Benner, MD

July 1st 1999

This phase I study was designed to determine the maximum tolerated dose (MTD) and dose-limiting side effects of combination treatment with paclitaxel (Taxol) and UFT (uracil and tegafur in a 4:1 molar ratio) plus oral

Infusional 5-FU, Folinic Acid, Paclitaxel, and Cisplatin for Metastatic

Ute Klaassen, MD;Hans Jochen Wilke, MD;Christian Müller, MD;David Borquez, MD;Michael Korn, MD;Klaus Diergarten, MD;Siegfried Seeber, MD, PhD

April 1st 1997

Our phase II study results demonstrating high efficacy and low toxicity for a weekly schedule of high-dose, 24-hour infusional 5-fluorouracil(5-FU)/folinic acid (HD5-FU/FA) in intensively pretreated patients with metastatic